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Abstract
Surgical site infections (SSIs) are among the most 
preventable health-care-associated infections 
and are a substantial burden to health-care sy-
stems and service payers worldwide in terms of 
patient morbidity, mortality, and additional costs. 
SSI prevention is complex and requires the inte-
gration of a range of measures before, during, 
and after surgery. No international guidelines 
are available and inconsistencies in the interpre-
tation of evidence and recommendations of na-
tional guidelines have been identified. Given the 
burden of SSIs worldwide, the numerous gaps in 
evidence-based guidance, and the need for stan-
dardisation and a global approach, WHO decided 
to prioritise the development of evidence-based 
recommendations for the prevention of SSIs. The 
guidelines take into account the balance between 
benefits and harms, the evidence quality, cost and 
resource use implications, and patient values and 
preferences. On the basis of systematic literature 
reviews and expert consensus, we present 23 re-
commendations on preoperative, intraoperative 
and postoperative preventive measures. The WHO 
recommendations were developed with a global 
perspective and they take into account the ba-
lance between benefits and harms, the evidence 
quality level, cost and resource use implications, 
and patient values and preferences.
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Introduction
Healthcare-associated infections (HAIs) are fre-
quent on surgical wards (1,2) and represent a high 
burden on patients and hospitals (1,3) in terms of 
morbidity, mortality, prolonged length of hospital 
stay and additional costs (4). HAIs are avoidable 
infections that affect hundreds of millions of pe-
ople each year worldwide. Following a systematic 
review of the literature and meta-analyses, WHO 
reported in 2010 that the prevalence of health-ca-
re-associated infections in low-income and midd-
le-income countries (LMICs) was two to 20 times 
higher than in high-income countries, affecting 
up to a third of patients who had surgery (5-7). Sur-
gical site infections (SSIs) are an important source 
(1) and may even be the most frequent HAI after 
excluding asymptomatic bacteriuria (8). Apart 
from endogenous risk factors, such as immune 
suppression (9-11), obesity (12) or advanced age 
(13), the role of external risk factors in SSI pathoge-
nesis is now clearly established (1,3). The incidence 
of SSI is much lower in high-income countries, but 
it is still the second most common cause of HAI in 
Europe and the USA (5,14). Furthermore, data from 
the USA showed that up to 60% of the microor-
ganisms isolated from infected surgical wounds 
have antibiotic resistance patterns (15). Multimo-
dal (16), multicentre or supranational preventive 
intervention programs based on guidelines (1,17), 
“bundles” (18,19) or safety checklists (20) are gai-
ning momentum on a global scale (21,22). In paral-
lel, randomized studies provide insight into poor-
ly explored risk factors and practical intervention 
measures. In 1999 SSI guidelines were published 
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by CDC (23). The National Institute for Health and 
Clinical Excellence (NICE) in England, Wales and 
Northern Ireland issued guidance for the preven-
tion and treatment of SSI in October 2008 (24).
Considering the epidemiological importance of 
SSIs, and the fact that these infections are largely 
preventable, WHO decided to prioritise the de-
velopment of evidence-based recommendations 
for the prevention of SSIs. Many factors in the pa-
tient’s journey through surgery contribute to the 
risk of SSI, and prevention is complex and requi-
res the integration of a range of measures before, 
during, and after surgery. Further strong reasons 
to develop global guidelines on this topic include 
the absence of any international guidance docu-
ment and inconsistencies in the interpretation of 
the evidence and strength of recommendations 
in national guidelines. In this review, the WHO re-
commendations for measures to be implemented 
or initiated during the preoperative period, will be 
presented. These were elaborated according to 
the best available scientific evidence and expert 
consensus with the aim to ensure high-quality 
care for every patient, irrespective of the resources 
available. In this review, the practical questions re-
garding the most effective measures to reduce SSI 
and the SSI rates achievable today are also addres-
sed, as well as the theoretical possibility of achie-
ving a zero SSI policy on a surgical ward, at least 
for clean orthopaedic surgery (3). 
Difficulties in Assessing Infections 
An active surveillance program is the cornerstone 
for the detection of HAI and accurate calculation of 
SSI rates within an institution. Unfortunately, there 
is no consensus on a universally accepted surveil-
lance strategy that would allow benchmarking of 
assessable infections (25). However, the National 
Nosocomial Infections Surveillance (NNIS) index 
for stratification could be useful, for example, and 
would represent at least an attempt to provide 
comparisons between hospitals (26). Surgical pa-
tients do not only acquire SSIs but they may be at 
higher risk to experience a HAI than nonsurgical 
patients, thus resulting in an additional burden on 
both the patient and the institution (27,28). If other 
institutional HAI rates remain unchanged or are in-
creasing, a reduction of SSI may have only a minor 
impact on patient safety. To reduce infections in 
surgical wards, an infection control strategy must 
target all HAIs, including less severe HAIs, such as 
urinary tract infections (2). 
Surveillance can be active, for example, by sche-
duled medical follow-up visits, or passive, but 
should be conducted within a minimum delay of 
30 days following surgery (1 year in the case of 
implant surgery (1)). Of note, programs without 
active post-discharge surveillance readily miss 
between 48 (29,30) and 79% of all SSIs (31,32). An 
additional problem is wound depth. While most 
surveillance strategies easily detect post-surgical 
deep or organ space infections, they often fail to 
record superficial infections (1,33). This is an im-
portant issue as these infections may represent 
up to 65% of the overall SSI burden in absolute 
numbers (34). Haematogenous infections are wi-
tnessed in implant-related surgery (35). Although 
these are ‘surgical site’ in terms of localization, 
they originate from other sites and might be in-
terpreted as primary SSIs if data are not validated 
by an expert. Finally, in surveillance programs ba-
sed on microbiological evidence alone, the use of 
sonication of implants may enhance and alter the 
proportion of microbiologically documented SSIs 
(36). In summary, the surveillance strategy has a 
large influence on infection rates: the more sophi-
sticated the strategy, the more likely the chance 
of detecting SSI and not to claim zero rates of HAI 
or SSI.
Current Benchmarks
The preventable proportion of HAI ranges from 10 
to 70% in the literature (37). So far, a complete ab-
sence of nosocomial infection over several mon-
ths has only been reported for catheter-related 
bloodstream infections (38,39). To the best of our 
knowledge, only one report has claimed almost 
zero SSI over an extended period of time (one of 
176 neurosurgical shunt operations) (40) and it 
would appear that this is not easy to achieve out-
side minimally invasive, ambulatory surgery (39). 
In general, emergency surgery (41), dirty contami-
nated surgery (1,42) and surgery in resource-poor 
settings (43-45) yield higher SSI rates than general 
or clean elective surgery in high-income coun-
tries, presumably because clean elective surgery 
is performed in soft tissues or bone structures that 
are not routinely colonized by bacteria.
Among all clean elective surgery, cataract (46) 
and orthopaedic surgery (13) have the fewest SSIs, 
with an overall crude incidence of 0.05 to 1.1%, 
respectively. According to a large prevalence stu-
dy in northern France, the relative SSI risk of ge-
nitourinary, cardiovascular, gynaecologic and ga-
strointestinal surgery compared with orthopaedic 
surgery was 2.1, 2.4, 2.6, 3.4 and 4.8, respectively 
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(13). Within the group of clean elective orthopae-
dic surgery, SSI risks may vary between different 
procedures. Arthroscopies harbour the absolute 
lowest SSI rates (0.1-0.4%) (3,42,47-49) and primary 
arthroplasties carry the lowest infection risk (0.5-
0.9%) for implant-related procedures (28,50-53). 
Differences in arthroplasty infection rates may de-
pend on the surveillance methods employed and 
the proportion of knee arthroplasties, which reve-
al a slightly higher infection risk than hip arthro-
plasties (35,53). The surveillance system used can 
also explain outliers, such as in the case of the Uni-
ted States Medicare system, with a documented 
lower incidence of primary arthroplasties (0.23%). 
However, only deep SSIs identified at 90 days 
post-implantation are reported in this system (54). 
Preventing SSI
Pathogenesis
Most SSIs are believed to be acquired during 
surgery (55). This is supported by the success of 
SSI prevention measures directed towards acti-
vities in the operating theatre and a few reports 
demonstrating matching strains of pathogens 
from the surgeon’s fingers and postoperative in-
fection (56,57). However, despite much research 
on SSI, there are currently no data on the actual 
proportion acquired in the operating theatre ver-
sus post-operative care on wards. Similarly, within 
the subgroup of SSIs acquired during surgery, the 
proportion originating from the patient versus 
that transmitted by the surgical staff, operating 
theatre procedure or the environment remains 
unknown. Among the most frequently cited risk 
factors are diabetes mellitus (16), age (13), obesity 
(12) and incorrect or lack of antibiotic prophylaxis 
(58); other mentioned factors, such as low socio-
economic status (59) or postoperative pain (60), 
have not been thoroughly investigated (61). It is 
likely that with the construction of large databases 
for nationwide surveillance programs, new and as 
yet unidentified risk factors will emerge from re-
search. Data on the clinical impact related to both 
endogenous and exogenous independent risk 
factors reveal risk indices oscillating between 1.3 
(13) and 4.5 (14). Approximately half of all identi-
fied risk factors are endogenous and difficult to 
modify in the immediate preoperative and perio-
perative phase. For exogenous risk factors, past 
experience has identified those with the best and 
least costly chance to decrease SSIs.
The Global Guidelines for the Prevention of Surgi-
cal Site Infection
The Global Guidelines for the Prevention of Sur-
gical Site Infection were developed by a panel 
of experts who reviewed the latest evidence on 
preventing SSIs. They include concrete recom-
mendations to be applied in the pre-, intra-, and 
postoperative periods. Until now, no international 
evidence-based guidelines had been published, 
and there are inconsistencies in the interpretation 
of evidence and recommendations regarding exi-
sting national guidelines.
The guidelines are valid for any country and are 
suitable for local adaptation. They take into ac-
count the strength of available scientific evidence, 
cost and resource implications, and patient values 
and preferences, the WHO says. The guidelines 
complement the WHO Surgical Safety Checklist by 
providing more detailed recommendations on SSI 
prevention, the agency says. The new guidelines, 
if implemented, will save lives, reduce harm, cut 
costs, and limit the spread of antibiotic resistance, 
the WHO predicts.
Pre-operative measures
1. Immunosuppressive agents commonly used for 
preventing the rejection of transplanted organs 
or for the treatment of inflammatory diseases 
could lead to impaired wound healing and an 
increased risk of infection in patients admi-
nistered these agents (62). By contrast, the di-
scontinuation of immunosuppressive treatment 
could induce flares of disease activity, and long-
term interruptions of therapy might induce the 
formation of anti-drug antibodies and subse-
quently decrease their effect (63).
2. The nutritional status of patients can lead to al-
terations in host immunity that can make them 
more susceptible to postoperative infections. 
Early nutritional support can improve the outco-
me of major surgery and decrease the incidence 
of infectious complications in selected malnou-
rished or severely injured patients (64,65).
3. Preoperative whole-body bathing or showe-
ring is considered to be good clinical practice 
to ensure that the skin is as clean as possible 
before surgery and reduce the bacterial load, 
particularly at the site of incision. In general, an 
antiseptic soap is used in settings in which it is 
available and affordable.
4. S aureus is one of, if not the most common he-
alth-care-associated pathogen worldwide, and 
can have severe consequences, including po-
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stoperative wound infection, nosocomial pneu-
monia, catheter-related bacteraemia, and incre-
ased mortality when it has meticillin resistance 
patterns (66-68). S aureus nasal carriage is a well 
defined risk factor for subsequent infection in 
various patient groups. Mupirocin nasal oint-
ment (usually applied twice daily for 5 days) is 
an effective, safe, and fairly cheap treatment for 
the eradication of S aureus carriage and is ge-
nerally used in combination with a whole body 
wash.
5. Mechanical bowel preparation (MBP) involves 
the preoperative administration of substances 
(polyethylene glycol and sodium phosphate are 
the most widely used) to induce voiding of the 
intestinal and colonic contents. It is commonly 
believed to reduce the risk of postoperative in-
fectious complications by decreasing the intra-
luminal faecal mass, thus theoretically decrea-
sing the bacterial load in the intestinal lumen. 
preoperative oral antibiotics should be used in 
combination with MBP in adult patients under-
going elective colorectal surgery to reduce the 
risk of SSI. MBP should not be done alone wi-
thout oral antibiotics. An activity against both 
facultative Gram-negative and anaerobic bacte-
ria should be guaranteed, and non-absorbable 
antibiotics should be used preferably.
6. Removal of hair from the intended site of sur-
gical incision has traditionally been part of the 
routine preoperative preparation of patients. 
Hair is perceived to be associated with poor cle-
anliness and SSIs. Although hair removal might 
be necessary to facilitate adequate exposure 
and preoperative skin marking, the method 
used can cause microscopic trauma of the skin 
and increase the risk of SSIs. Hair should either 
not be removed or, if absolutely necessary, it 
should be removed only with a clipper. Shaving 
is strongly discouraged at all times, whether 
preoperatively or in the operating room.
7. Surgical antibiotic prophylaxis (SAP) refers to 
the prevention of infectious complications by 
administering an antimicrobial agent before 
exposure to contamination during surgery (69). 
Successful SAP requires delivery of the antimi-
crobial agent in effective concentrations to the 
operative site through intravenous administra-
tion at the appropriate time. The half-life of the 
agent used, the underlying condition(s) of the 
individual patient (eg, bodymass index, or renal 
or liver function), the time needed to comple-
te the procedure, and the protein binding of 
the antibiotic should be taken into account to 
achieve adequate serum and tissue concentra-
tions at the surgical site at the time of incision 
and up to wound closure – in particular to pre-
vent incisional SSI.
8. Surgical hand preparation is vitally important 
to maintain the least possible contamination 
of the surgical field, especially in the case of 
sterile glove puncture during the procedure. 
Surgical hand preparation should be done ei-
ther by scrubbing with a suitable antimicrobial 
soap and water or using a suitable alcohol-ba-
sed hand rub before donning sterile gloves. 
However, the rapid antimicrobial action, wider 
spectrum of activity, lower side effects and the 
absence of the risk of hand contamination by 
rinsing water in resource-poor areas might fa-
vour alcohol-based solutions (21,70,71). Brushes 
are not recommended for surgical hand prepa-
ration (21,70,72). 
9. The aim of surgical site skin preparation is to 
reduce the microbial load on the patient’s 
skin as much as possible before incision of the 
skin barrier. The most common agents include 
chlorhexidine gluconate and povidone-iodine 
in alcohol-based solutions. Operating room 
staff should be trained and informed about the 
potential harms associated with the solutions 
used for surgical site preparation. Alcohol-ba-
sed solutions should not be used on neonates 
or come into contact with mucosa or eyes, and 
caution should be exercised because of their 
flammable nature. Chlorhexidine gluconate so-
lutions can cause skin irritation and must not 
be allowed to come into contact with the brain, 
meninges, eye, or middle ear.
10. Antimicrobial skin sealants are sterile, film-for-
ming cyanoacrylate-based sealants commonly 
applied as an additional antiseptic measure 
after using standard skin preparation on the 
surgical site and before skin incision. They are 
intended to remain in place and block the mi-
gration of flora from the surrounding skin into 
the surgical site by dissolving over several days 
postoperatively. Antimicrobial sealants should 
not be used after surgical site skin preparation 
for the purpose of reducing SSIs.
Peri-and post-operative measures
1. Adequate surgical site tissue oxygenation is 
thought to have a role in preventing SSIs. A 
high partial pressure of oxygen in the blood 
achieved through the administration of hi-
JAnuARy 2017 | volume 5 | issue 1 |    © life sAfety And secuRity  ISSN: 2283-7604 | DOI: 10.12882/2283-7604.2017.5.1 5
Av
ai
la
bl
e 
on
lin
e 
at
 h
tt
p:
//
w
w
w
.ie
m
es
t.e
u/
lif
e-
sa
fe
ty
-a
nd
-s
ec
ur
it
y/
gh-concentration oxygen (hyperoxia, defined 
as oxygen at 80% FiO2) provides more adequate 
oxygenation at the surgical incision – particular-
ly at infected tissue (73), which has a lower oxy-
gen tension than non-infected tissues (74) – and 
might enhance oxidative killing by neutrophils. 
Patients undergoing general anaesthesia with 
endotracheal intubation for surgical procedures 
should receive 80% FiO2 intraoperatively and, if 
feasible, for 2-6 h in the immediate postopera-
tive period.
2. Hypothermia is defined as a core temperature 
less than 36°C. It commonly occurs during and 
after surgical procedures lasting more than 2 h 
because of impairment of thermoregulation by 
anaesthesia, combined with exposure to a cold 
environment (the operating room) (75,76). Unin-
tended hypothermia is considered to be an ad-
verse event of general and regional anaesthesia 
and might be associated with increased cardiac 
complications, blood loss due to impaired co-
agulation, impaired wound healing, decreased 
drug metabolism, decreased immune function, 
and an increased risk of SSI (75,77-80).
3. A rise in blood glucose concentration is com-
monly observed in the operative and posto-
perative periods because of a surgical stress 
response, resulting in increased secretion of 
catabolic hormones (eg, catecholamines or 
cortisol), inhibition of insulin secretion, and in-
sulin resistance (81). Observational studies have 
shown that hyperglycaemia is associated with 
an increased risk of SSIs in both diabetic and 
non-diabetic patients (82-84). Using a protocol 
with strict blood glucose target concentrations 
is associated with a substantial benefit for the 
reduction of SSI prevalence. Hypoglycaemia is a 
possible serious side-effect associated with the-
se intensive protocols and close reliable moni-
toring of blood glucose concentrations is crucial 
for this intervention.
4. Adequate intravascular volume is an essen-
tial component of tissue perfusion and an im-
portant aspect of tissue oxygenation (85). In 
unbalanced fluid states – ie, hypovolaemia and 
hypervolaemia – tissue oxygenation is compro-
mised and might increase the risk of SSI (86). 
The use of goal-directed fluid therapy intraope-
ratively reduces the risk of SSI.
5. Drapes and gowns are available for single-u-
se or multiple-use, with varying compositions. 
Adhesive plastic incise drapes are used on a pa-
tient’s skin after surgical site preparation, with 
or without antimicrobial impregnation, and 
the surgeon performs the incision of the drape 
and the skin simultaneously. Either sterile di-
sposable non-woven or sterile reusable woven 
drapes and gowns can be used. Adhesive incise 
drapes (with or without antimicrobial proper-
ties) should not be used for the purpose of pre-
venting SSI.
6. Wound-protector devices (or wound-edge 
protectors) are comprised of a non-adhesive 
plastic sheath attached to a single or double 
rubber ring that firmly secures the sheath to 
the wound edges. They facilitate the retraction 
of the incision during surgery and are aimed at 
reducing wound-edge contamination to a mi-
nimum during abdominal surgical procedures. 
Wound-protector devices are recommended in 
clean-contaminated, contaminated, and dirty 
abdominal surgical procedures for the preven-
tion of SSI.
7. Intraoperative wound irrigation refers to the 
flow of a solution across the surface of an open 
wound. It is a widely practised procedure and 
considered to help prevent SSIs (87-89). Among 
other benefits, wound irrigation is intended to 
physically remove cellular debris, surface bacte-
ria, and body fluids, to dilute possible contami-
nation, and to function as a local antibacterial 
agent when an antiseptic or antibiotic agent 
is used. Incisional wound irrigation with an 
aqueous povidone-iodine solution might have 
a benefit, particularly in clean and clean-conta-
minated wounds. Antibiotic incisional wound 
irrigation before closure should not be used for 
the purpose of preventing SSI. This practice is 
associated with an unnecessary risk of antimi-
crobial resistance. Allergic reactions and me-
tabolic adverse events should be considered 
as potential harms of iodine uptake. Current 
evidences are insufficient to recommend for or 
against saline irrigation of incisional wounds for 
the purpose of preventing SSIs. 
8. Prophylactic negative-pressure wound therapy 
(pNPWT) consists of a closed sealed system 
connected to a vacuum pump, which main-
tains negative pressure on the wound surface. 
The use of pNPWT on primarily closed surgical 
incisions in high-risk conditions (eg, poor tissue 
perfusion due to surrounding soft tissue or skin 
damage, decreased blood flow, bleeding or ha-
ematoma, dead space, or intraoperative conta-
mination) is recommended for the purpose of 
the prevention of SSIs, taking available resour-
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ces into account.
9. Sutures with antimicrobial properties were de-
veloped with the aim to prevent microbial co-
lonisation of the suture material in operative 
incisions. Early studies showed a reduction of 
the number of bacteria in vitro and wound in-
fections in animals (90-92) using triclosan-co-
ated sutures and this effect was subsequently 
confirmed in clinical studies. Several novel an-
timicrobial coatings are now available, but still 
no clinical studies have been done that compa-
re the efficacy with non-coated sutures (93,94). 
The use of antimicrobial-coated sutures for the 
purpose of reducing the risk of SSI is recom-
mended. Because the effect appears to be in-
dependent of the type of procedure or wound 
contamination classification, this recommenda-
tion applies to any type of surgery.
10. Conventional ventilation systems pass air with 
a mixed or turbulent flow into the operating 
room. These systems aim to homogenise the 
fresh air, the air, and aerosols and particles wi-
thin the room. Laminar airflow systems pass 
the fresh air unidirectionally with a steady ve-
locity and approximately parallel streamlines 
to create a zone in which the air, aerosols, and 
particles within the room are driven out. Sy-
stems with laminar airflow are frequently used 
in an environment where contamination with 
particles is a serious adverse event – eg, ortho-
paedic implant surgery. However, laminar air-
flow systems are complex and expensive and 
require careful maintenance. Laminar airflow 
ventilation systems should not be used as a 
preventive measure to reduce the risk of SSI 
in patients undergoing total arthroplasty sur-
gery.
11. Drainage tubes are widely used in surgery to 
remove any fluid or blood that collects in the 
wounds and cavities created by the surgical 
procedure and thus might cause complica-
tions. However, drains might adversely affect 
surgical outcomes – eg, affecting anastomotic 
healing by causing infection in the anasto-
motic area and the abdominal wound. Many 
systematic reviews investigating the effect of 
drains on the related infection risk compared 
with no wound drainage have been published 
with conflicting results. The optimal time for 
drain removal after surgery might influence 
this risk, but it remains unknown. Furthermore, 
in most cases, antibiotic prophylaxis is conti-
nued postoperatively when a drain is used, but 
this practice is not evidence-based and raises 
serious concerns in terms of contributing to 
the emergence of antimicrobial resistance. an-
tibiotic prophylaxis should not be continued in 
the presence of a wound drain for the purpose 
of preventing SSI. Wound drains should be re-
moved when clinically indicated.
12. A wide variety of wound dressings are avai-
lable. Advanced dressings are mainly hydro-
colloid, hydrogels, fibrous hydrocolloid, or 
polyurethane matrix hydrocolloid dressings 
and vapour-permeable films. Advanced dres-
sings should not be used for the prevention of 
SSIs.
13. The preventive effect of the routine use of SAP 
has long been recognised; however, the neces-
sary duration of SAP to achieve the desired ef-
fect has been a matter of debate. Most guide-
lines recommend a maximum postoperative 
SAP duration of 24 h, but increasing evidence 
shows that using only a single preoperative 
dose (and possible additional intraoperative 
doses according to the duration of the ope-
ration) might be non-inferior. Despite this, 
surgeons still often routinely continue SAP up 
to several days after surgery, which leads to 
serious concerns for the risk of antimicrobial 
resistance. SAP prolongation should be avoi-
ded, also because of the widespread risk of 
antimicrobial resistance. Continuing antibio-
tic administration in cardiac and orthognathic 
surgery has potential benefit, but further well 
designed RCTs on this topic are needed.
Other Measures with High Efficacy
Expertise of the Surgeon
The surgeon’s expertise and surgical technique is 
probably very important, although subjective and 
difficult to analyse (17). Furthermore, it is almost 
impossible to perform a randomized trial on this 
subject. An excellent surgical technique is belie-
ved to reduce SSI by: maintaining effective hae-
mostasis while preserving adequate blood supply; 
gentle handling of tissue; removal of devitalized 
tissue; eradication of dead space; and appropria-
te management of the postoperative incision (1). 
These techniques can be learned and it has been 
suggested since the mid-1980s that surgical simu-
lation has a beneficial impact on surgeons’ expe-
rience and performance (95). 
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Active Surveillance with Feedback
Decreases in SSI rates have been observed in natio-
nal surveillance networks in European countries, 
such as France (13,29,96,97), Germany (42,98) and 
The Netherlands (31,32,99). An active surveillance 
programme may decrease SSI rates by merely re-
porting data without any other formal interven-
tions (29). Some experts question whether studies 
using data from national surveillance networks 
can be used to support the effectiveness of sur-
veillance with feedback as there is no information 
about other interventions implemented in the 
many hospitals that have contributed to the data. 
However, the reports do not mention these theo-
retical aspects. In 1985, the Study on the Efficacy 
of Nosocomial Infection Control (SENIC) showed 
that the presence of a dedicated infection control 
team, together with surveillance and feedback of 
observed data, resulted in a 38% decrease of SSIs 
among participating hospitals (100). However, the 
structural mechanism of implementing such a stra-
tegy is complex and requires engineering chan-
ges in behavioural (98) as well as system aspects. 
In addition, it differs according to the setting and 
takes several years to develop gradually to its full 
effectiveness (42,97), although the impact can be 
very powerful, with reports ranging from a 25 (42) 
to 50% decrease in SSI rates (97) within 4-6 years 
following implementation.
Multimodal Intervention
Instead of targeting single risk factors, it is advi-
sed to target several at the same time, although 
they are usually based on pre-/post intervention 
studies and not randomized trials or meta-analy-
ses. Multimodal interventions, sometimes in the 
form of so-called “bundles”, have become very 
popular in recent years (101). A variant are safety 
check-lists (20) that have been inspired from the 
airline industry. The multimodal approach does 
not need to cover all potential risk factors. Local 
(10,16), nationwide (“100k lives campaign” (18) 
and Surgical Care Improvement Project (9,19)) and 
global (World Health Organization Global Patient 
Safety Challenges “Clean Care is Safer Care” and 
“Safe Surgery Saves Lives” (20,22)) intervention 
programs rely on only three to six key targets and 
have achieved substantial results. For example, 
Trussell et al. implemented a quality care initiati-
ve including peri-incisional antibiotic prophylaxis, 
close glucose control and hair clipping and repor-
ted 1.5% SSIs in the intervention group compared 
with 3.5% in the comparator arm (16). The USA’s 
100k lives program recommended correct anti-
biotic prophylaxis, glucose control and intraopera-
tive normothermia, and achieved a 27% reduction 
in SSI rates (18). Globally, the WHO strategies are 
effective through education programs, use of al-
cohol-based hand rub and access to safe surgical 
care. Multimodal interventions based on bundles 
or checklists are the strategy with the highest im-
pact in terms of SSI prevention.
Postponing Elective Surgery in the Case of Sympto-
matic Remote Infection
This issue is regarded as high evidence in the CDC 
guidelines (1), although there are no randomized 
trials on the topic of postponing to the best of 
our knowledge. However, a number of case series 
and retrospective studies exist reporting a hae-
matogenous origin for total joint arthroplasty in-
fections and secondary infections of other ortho-
paedic implants. Although the incidence of true 
haematogenous arthroplasty infections in the 
case of active remote infection is probably lower 
than formerly believed (35,102), most experts 
agree that elective surgery should be postponed 
until the remote infection is cured. The necessity 
to postpone in the case of asymptomatic bacte-
riuria (103) or even urinary tract infection (104) in 
elective orthopaedic surgery or nonimplant-re-
lated surgery is less certain. Common sources of 
haematogenous implant infections are often the 
skin, the GI tract or the lungs (35).
Other Measures yet to be Confirmed in Future Trials
Several new approaches show promising resul-
ts in randomized trials, but have been reported 
only once or on very few occasions. As an exam-
ple, Dutch investigators reported that naso- and 
oropharynx decontamination with chlorhexidine 
before cardiac surgery significantly lowered deep 
SSIs, bacteraemia and lower respiratory tract in-
fections (105). This needs confirmation in further 
trials as a similar approach failed to show any be-
nefit for ventilator-associated pneumonia (106). 
Further concerns about the potential for chlorhexi-
dine resistance, in particular among staphylococ-
ci, require further study and explanation (107). 
The future will show if continuous, positive airway 
pressure during anaesthesia significantly lowers 
the risk for several HAIs by avoidance of postope-
rative hypoxemia (108). Another debate concerns 
whether minimal invasive surgery or the use of 
laparoscopy versus laparotomy may lower SSI risk 
(42,101,109). 
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Conclusion
Zero HAI (or zero SSI) is theoretically possible in 
clean elective surgery, but there is no published 
report so far of zero infection in a surgical unit over 
a prolonged period. All HAIs have to be targeted, 
thus requiring different prevention programs con-
ducted at the same time. This goal requires multi-
disciplinary, multifaceted commitment, dedicated 
infection control teams and efforts, and institu-
tional and behavioural elements to ensure sustai-
nability. National surveillance networks may help 
benchmarking. Current benchmarks for SSI are 
0.1% risk in arthroscopy and cataract surgery. A 
multimodal approach is recommended, including 
optimized antibiotic prophylaxis, active post-di-
scharge surveillance and continuous performan-
ce feedback. The future of SSI prevention will 
certainly be marked by multimodal, multicenter 
or national intervention programs, bundles (1,18) 
and checklists (20) targeting not only SSIs, but 
also various nosocomial infections among patien-
ts exposed to surgical procedures. SSIs will beco-
me an integral issue of patient safety (22) not only 
in the operating theatre, but also up to hospital 
discharge and beyond. With the rise of same-day 
surgery, ambulatory patients will be included in 
these programs more frequently. Active post-di-
scharge surveillance, the standardization of sur-
veillance protocols and enhanced funding are pre-
requisites to set up and conduct these programs 
that will prove cost effective in the long-term. Rai-
sing awareness at different levels, including local/
national authorities and the public, may trigger 
efforts for reporting SSIs and international bench-
marking, and thus possibly contribute towards a 
further decrease of current infection rates. These 
interventions do not require new sophisticated te-
chnology. An improved adherence to established 
basic principles such as surgical hand preparation, 
skin antisepsis, adequate antibiotic prophylaxis, 
less traumatic, less invasive and shorter surgery 
duration, improved haemostasis and avoidance of 
hypothermia or hyperglycaemia will remain cor-
nerstones, while decolonization of various patient 
body sites may soon find its place in the armen-
tarium (101). The relatively highest achievements 
will be obtained in resource-poor countries than-
ks to individual initiatives, national programs and 
WHO-directed interventions (21,22). Surgeons’ 
technical skills and non-invasive techniques will 
continuously improve as a result of ever-increasing 
professional training, including mandatory mo-
nitored performance skills or simulation models 
resulting in increased overall patient safety (95). 
From an academic standpoint, we still lack a com-
plete understanding of exactly when the surgical 
site starts to develop infection, what the premises 
that drive microbial colonization to infection are 
and why some patients get infected and others 
do not. There is certainly enough room to impro-
ve work up of the pathogenesis, search for hidden 
risk factors lurking inside large databases and to 
implement well-conducted randomized studies. 
Although the guidelines are intended for surgical 
patients of all ages, some recommendations do 
not apply to the paediatric population, owing to 
lack of evidence or inapplicability. This is clearly 
stated in the guidelines. No one should get sick 
while seeking or receiving care. Preventing surgi-
cal infections has never been more important, but 
it is complex and requires a range of preventive 
measures. These guidelines are an invaluable tool 
for protecting patients. The WHO’s next step will 
be to work with countries and experts to prepare 
an implementation guide and assessment toolkit.
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